Overview
Dengue hemorrhagic fever (DHF), particularly in its most severe form known as Dengue Shock Syndrome (DSS), grade IV, represents a critical public health concern with evolving epidemiological patterns. Traditionally endemic in tropical and subtropical regions, the incidence of dengue has expanded to include non-endemic areas such as large urban centers in Argentina, highlighting the need for heightened vigilance and preparedness among healthcare providers globally [PMID:42028955]. This condition predominantly affects younger populations, with distinct clinical presentations and management challenges observed across different age groups. Understanding the epidemiology, clinical manifestations, management strategies, and potential complications is crucial for optimizing patient outcomes.
Epidemiology
The epidemiology of dengue, especially DSS grade IV, reveals significant shifts in affected demographics and geographic distribution. Younger patients, particularly those under 20 years of age, are disproportionately affected and exhibit different treatment patterns compared to older patients. For instance, younger patients are more likely to receive treatments such as nonsteroidal anti-inflammatory drugs (NSAIDs) and hypotonic intravenous fluids, which may not align with current best practices [PMID:31701854]. This trend underscores the importance of age-specific considerations in clinical management. Additionally, the emergence of dengue in previously non-endemic regions like Argentina underscores the global spread of the virus, driven by factors such as urbanization, increased travel, and climate change [PMID:42028955]. Clinicians must remain alert to these evolving patterns to ensure timely diagnosis and intervention.
Clinical Presentation
The clinical presentation of Dengue Shock Syndrome (DSS), particularly in its most severe grade IV, varies significantly based on patient age and can include a range of systemic manifestations. In pediatric patients, acute renal failure (ARF) is a notable complication that requires vigilant monitoring and prompt intervention, as highlighted by recent studies [PMID:36645744]. Adolescents (≥10 years) often present with more pronounced symptoms such as headache, musculoskeletal pain, and abdominal pain compared to younger children, indicating a possible age-related difference in symptomatology [PMID:42028955]. Furthermore, elevated transaminases are more frequently observed in children under 10 years, suggesting a higher likelihood of liver involvement in this age group [PMID:42028955]. These findings emphasize the need for tailored clinical assessments and monitoring strategies based on patient age to detect and manage complications effectively.
Diagnosis
Diagnosing DSS grade IV involves a combination of clinical criteria and laboratory findings. Clinicians typically rely on the World Health Organization (WHO) classification system, which includes clinical features such as high fever, hemorrhagic manifestations, thrombocytopenia, and evidence of plasma leakage (e.g., pleural effusion, ascites, or hypovolemic shock) [Evidence: Expert opinion]. Laboratory tests play a crucial role, with thrombocytopenia, elevated liver enzymes, and hematocrit levels fluctuating due to fluid shifts being common indicators [PMID:42028955]. Early identification of warning signs such as mucosal bleeding, persistent vomiting, and severe abdominal pain is critical, as these symptoms were present in 34% of patients and signal the potential progression to severe complications [PMID:42028955]. Rapid diagnostic tests (RDTs) for dengue virus NS1 antigen and serological markers (IgM and IgG antibodies) can aid in early diagnosis, although definitive confirmation often requires RT-PCR or viral isolation in specialized laboratories.
Management
The management of DSS grade IV requires a multifaceted approach focused on fluid resuscitation, monitoring for complications, and adherence to evidence-based guidelines. Prompt fluid resuscitation with isotonic fluids is paramount to stabilize hemodynamics and prevent shock [PMID:36645744]. Studies indicate that addressing fluid overload early is crucial, as it significantly mitigates the risk of acute respiratory failure post-shock stabilization in pediatric patients [PMID:36645744]. However, there is a concerning trend where hypotonic intravenous fluids and NSAIDs are still administered despite WHO recommendations against these practices, with 24.5% of dengue fever (DF) patients and 48.4% of DHF patients receiving hypotonic fluids, and 12.9% and 18.8% receiving NSAIDs, respectively [PMID:31701854]. These deviations can elevate the risk of adverse events, emphasizing the need for strict adherence to guidelines. Additionally, platelet transfusions, while sometimes considered in severe cases, are used disproportionately in younger patients (17.2% in those <20 years vs. 1.3% overall), indicating a potential overutilization that warrants further scrutiny [PMID:31701854]. Hospitalization rates among confirmed dengue cases highlight the necessity for early identification and risk stratification, with 15% requiring inpatient care [PMID:42028955].
Complications
DSS grade IV is associated with several severe complications that can significantly impact patient outcomes. Fluid accumulation, defined as a ≥10% increase in fluid balance adjusted for body weight within the first 24 hours of PICU admission, is a notable risk factor for acute respiratory failure (ARF) in pediatric patients, as demonstrated by retrospective studies [PMID:36645744]. This underscores the importance of meticulous fluid management to prevent respiratory complications. Other critical complications include gastrointestinal bleeding, shock, and organ dysfunction, often signaled by warning signs such as mucosal bleeding, persistent vomiting, and severe abdominal pain, which were observed in 34% of patients [PMID:42028955]. The use of non-recommended treatments like hypotonic fluids and NSAIDs further elevates the risk of adverse events, including electrolyte imbalances and exacerbation of hemorrhage, highlighting the need for strict adherence to evidence-based guidelines to mitigate these risks [PMID:31701854].
Prognosis & Follow-up
The prognosis for patients with DSS grade IV can vary widely depending on the timeliness and effectiveness of interventions. While early and appropriate management significantly improves outcomes, complications such as fluid accumulation remain significant risk factors for adverse events like ARF [PMID:36645744]. Larger prospective cohort studies are needed to further elucidate causality and refine management strategies, particularly in identifying high-risk patients and optimizing supportive care protocols [PMID:36645744]. Post-discharge follow-up is essential to monitor for delayed complications and ensure full recovery. Regular clinical assessments, laboratory monitoring, and patient education on signs of relapse or complications are crucial components of long-term management [Evidence: Expert opinion].
Key Recommendations
References
1 Preeprem N, Phumeetham S. Paediatric dengue shock syndrome and acute respiratory failure: a single-centre retrospective study. BMJ paediatrics open 2022. link 2 Kajimoto Y, Kitajima T. Clinical Management of Patients with Dengue Infection in Japan: Results from National Database of Health Insurance Claims. The American journal of tropical medicine and hygiene 2020. link 3 Carril SS, Bonnin FA, Tineo MS, Antonelli Sanz AS, Denardi A, Marin A et al.. Pediatric Dengue in Buenos Aires During the 2024 Outbreak: Clinical Presentation, Laboratory Findings, Viral Load, and Preexisting Immunity. Journal of the Pediatric Infectious Diseases Society 2026. link